ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target

 ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop
 and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema

  PR Newswire

  LEUVEN, Belgium, September 5, 2013

LEUVEN, Belgium, September 5, 2013 /PRNewswire/ --

ThromboGenics NV (Euronext Brussels: THR:BR), a biopharmaceutical company
focused on developing and commercializing innovative ophthalmic medicines,
today announces that it has entered into a collaboration and license agreement
with Bicycle Therapeutics to develop and commercialize novel drugs inhibiting
a specific target for the treatment of ophthalmic diseases, such as diabetic
macular edema (DME). DME is a leading cause of adult vision loss, with a
significant proportion of patients failing to respond adequately to existing
therapies for this condition.

ThromboGenics intends to develop therapeutics based on Bicycle's bicyclic
peptides, which inhibit a target involved in vascular permeability. Selective
inhibition of this target represents a new approach that offers the potential
to improve the treatment of DME. ThromboGenics and Bicycle will collaborate on
the preclinical development of these bicyclic peptide inhibitors.

DME is a common consequence of diabetic retinopathy and a leading cause of
significantly impaired vision among patients with diabetes. Globally, 350
million people are estimated to suffer from diabetes (WHO). An estimated 30%
of all patients suffering from diabetes for over 20 years are at risk of
developing DME.

For many years, the standard of care has been to treat DME with laser
photocoagulation to the macula. More recently, it has been shown that
injectable intravitreal drugs that inhibit vascular endothelial growth factor
(VEGF) are effective in the treatment of DME. ThromboGenics has gained an
exclusive license from Bicycle to undertake clinical development and
commercialization of identified drug candidates.

ThromboGenics will pay Bicycle an undisclosed upfront fee, development and
regulatory milestone payments and royalties on sales of products resulting
from the collaboration.

Dr Patrik De Haes, CEO of ThromboGenics, said: " This new agreement is further
evidence of our commitment to develop and commercialize novel therapeutics
targeting unmet needs in the treatment of diabetic eye diseases, such as DME.
We are looking forward to evaluating these bicyclic peptides, with the aim of
progressing clearly differentiated drug candidates through to the next stages
of development. "

Commenting on today's announcement, Dr Rolf Guenther, CEO of Bicycle
Therapeutics, said: " We have used the Bicycle technology platform to identify
and optimize highly selective bicyclic peptides that inhibit a target involved
in vascular permeability in the picomolar range. I am delighted to enter this
collaboration with Thrombogenics, a partner with a focus and successful track
record in developing novel ophthalmic therapeutics, and look forward, in time,
to progressing drug candidates into the clinic " .

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing
and commercializing innovative ophthalmic and oncology medicines. The
Company's lead product, JETREA ^® (ocriplasmin), has been approved by the US
FDA for the treatment of symptomatic VMA and was launched in January 2013. 

ThromboGenics signed a strategic partnership with Alcon (Novartis) for the
commercialization of JETREA ^® outside the United States. Under this
agreement, ThromboGenics could receive up to a total of €375 million in
up-front and milestone payments. It will receive significant royalties from
Alcon's net sales of JETREA ^® . ThromboGenics and Alcon intend to share the
costs equally of developing JETREA ^® for a number of new vitreoretinal
indications.

In Europe, JETREA ^® is approved for the treatment of vitreomacular traction
(VMT), including when associated with macular hole of diameter less than or
equal to 400 microns. Alcon has launched JETREA ^® in the UK, Germany,
Denmark, Norway, Finland and Sweden. 

ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor),
also referred to as TB-403.

ThromboGenics is headquartered in Leuven, Belgium, and has-offices in Iselin,
NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext
Brussels exchange under the symbol THR. More information is available at
http://www.thrombogenics.com .

About Bicycle Therapeutics

Bicycle Therapeutics has developed a proprietary bicyclic peptide based
technology that enables the discovery of a new class of drug candidates
('bicycles') providing antibody-like affinity and selectivity in a much
smaller chemically synthesized molecule. Bicycle peptides are short peptide
sequences constrained by a chemical scaffold core to form a structure with two
loops of amino acids. This structure confers high stability and high affinity
binding to targets. The company is applying the technology to drug discovery
projects in areas including oncology and ophthalmology and additional
therapeutic areas through selected collaborative discovery partnerships with
pharma companies.

Bicycle's technology is based on the work performed at the MRC Laboratory of
Molecular Biology in Cambridge by the scientific founders of the company,
Prof. Christian Heinis and Sir Gregory Winter. The company is funded by Atlas
Venture, Novartis Venture Fund, SVLS, SR One and Astellas Venture Management.
For more information visit http://www.bicycletherapeutics.com .

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking".
Such forward-looking statements are based on current expectations, and,
accordingly, entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or any other reason. Additional information concerning risks and
uncertainties affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is contained
in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or
purchase of securities or assets of ThromboGenics in any jurisdiction.  No
securities of ThromboGenics may be offered or sold within the United States
without registration under the U.S. Securities Act of 1933, as amended, or in
compliance with an exemption therefrom, and in accordance with any applicable
U.S. state securities laws.

For further information please contact:

ThromboGenics

Wouter Piepers, Global Head of Corporate Communications +32-16-75-13-10 /
+32-478-33-56-32 Wouter.piepers@thrombogenics.com Dr. Patrik De Haes, CEO
+32-16-75-13-10 Patrik.dehaes@thrombogenics.com Chris Buyse, CFO
+32-16-75-13-10 Chris.buyse@thrombogenics.com

Citigate Dewe Rogerson David Dible/ Sita Shah Tel: +44-20-7638-9571
sita.shah@citigatedr.co.uk

The Trout Group (US investor relations) Todd James/ Simon Harnest Tel:
+1-646-378-2926 tjames@troutgroup.com
 
Press spacebar to pause and continue. Press esc to stop.